Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 536

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 536
---
4, Cara entered into a Consent to Lease Assignment and Amendment to Lease with the Landlord and an Assignment and Assumption of Lease Agreement, or the Assignment Agreements, in which Cara’s corporate lease, leasehold improvements, and other property and equipment from Cara’s corporate office were transferred to a third party on November 1, 2024 (see Note 17 of Cara’s Notes to Condensed Consolidated Financial Statements as of September 30, 2024, Commitments and Contingencies — Assignment of New Lease , included elsewhere in this proxy statement/prospectus).

<div align='center'>313</div>

TABLE OF CONTENTS

Cara’s Product Portfolio

| Product                                    | ​ | ​ | Indication                  | ​ | ​ | Status                                                                                        | ​ | ​ | Next Milestone | ​ | ​ | Commercialization Rights                           | ​ |
| KORSUVA (difelikefalin) injection/Kapruvia | ​ | ​ | Pruritus CKD — Hemodialysis | ​ | ​ | Approved in the U.S. (08/2021)                                                                
 Approved in EU incl. UK (04/2022)                                                             
 Approved in Japan (09/2023)                                                                   
 Other approvals: Switzerland, Canada, Singapore, Australia, Kuwait, Israel, UAE, Saudi Arabia | ​ | ​ | ​              | ​ | ​ | CSL Vifor (Worldwide excl. Japan and South Korea)* 
 Maruishi (Japan)                                   
 CKDP (South Korea)                                 | ​ |

* Cara is party to two collaborations for the commercialization of KORSUVA (difelikefalin) injection/ Kapruvia with a joint venture between CSL Vifor and Fresenius Medical Care. In this section, unless the context otherwise requires, “CSL Vifor” refers to CSL Vifor and its affiliated entities, including, where applicable, the joint venture. KORSUVA (difelikefalin) injection — Cara’s Commercial Stage Product Overview Cara has out-licensed to CSL Vifor the commercialization of KORSUVA injection/Kapruvia in dialysis patients with moderate-to-severe pruritus associated with chronic kidney disease, or advanced CKD-aP, worldwide, excluding Japan (licensed to Maruishi/sub-licensee Kissei), and South Korea (licensed to CKDP). On August 23, 2021, KORSUVA injection was approved by the U.S. Food and Drug